Our goal is to make whole genome sequencing the norm, not the exception.
genomiQa offers hospitals, clinicians and companies high-quality analysis of data from whole genome sequencing. We bring promising research and precision analytics to routine clinical practice.
genomiQa is a start-up company that has grown out of the QIMR Berghofer Medical Research Institute—now a major shareholder and where genomiQa is based.
Founders, Dr Nic Waddell and John Pearson, have more than 35 years’ combined experience in genomics and bioinformatics. These areas of expertise blend powerfully within genomiQa’s products and services, which are designed to support personalised treatment and better outcomes for patients.
Dr Nic Waddell is a leader in interpreting whole genome next generation sequence data, with multiple Nature publications. Her ongoing research focuses on identifying mutational processes and therapeutic opportunity in a variety of cancer types. She works toward her goal to see quality genomics implemented into clinical settings.
John has created software for medical researchers and has developed analysis pipelines for whole genome, exome and panel sequencing. He has worked with next-generation sequencing projects in the USA and Australia, and has been involved in the 1000 Genomes Project and the International Cancer Genome Consortium (ICGC).
Colin has global, start-up and extensive commercial experience across the Asia-Pacific. His previous roles included leading strategy and business initiatives in China, APAC Commercial Head and Regional General Manager for the launch of Foundation Medicine in APAC for Roche Pharmaceuticals.